TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

TAVR programs follow inconsistent DNR policies, potentially skewing data

Not all hospitals respect the written preferences of patients, possibly motivated by a desire to report better TAVR outcomes.

Thumbnail

Moderate aortic stenosis linked to a significant risk of death—should earlier interventions be considered?

Researchers tracked data from more than 12,000 moderate AS patients who originally participated in one of 25 different studies. While the findings seem to suggest earlier treatment could be beneficial for certain high-risk patients, additional research is still required.

SAPT after TAVR preferred over DAPT, new meta-analysis confirms

An international team of researchers, led by specialists from Cleveland Clinic, found that DAPT was consistently linked to a greater risk of major or life-threatening bleeding events. 

Thumbnail

Cardiac surgeons gaining procedural volume despite TAVR making up 84% of cases

A decade ago, when TAVR was first cleared by the FDA, surgeons had concern about losing business. But unexpectedly, TAVR has helped also gain heart surgery cases. 

Mitral annular calcium (MAC) does not appear to have a negative effect on long-term transcatheter aortic valve replacement (TAVR) outcomes, according to new research published in the American Journal of Cardiology.

TAVR safe and effective for patients presenting with mitral annular calcium

Researchers from Cleveland Clinic reviewed data from more than 400 patients, presenting their findings in the American Journal of Cardiology.

Performing valve-in-valve transcatheter mitral valve replacement (ViV TMVR) with conscious sedation (CS) or monitored anesthesia care (MAC) instead of general anesthesia (GA) is safe and effective, according to new research published in JACC: Cardiovascular Interventions.

Using a TAVR-like minimalist approach for valve-in-valve TMVR is safe and effective, Cleveland Clinic study confirms

During valve-in-valve TMVR, patients are treated with conscious sedation or monitored anesthesia care instead of general anesthesia. This new analysis confirms that the change does not impact patient outcomes, but it was linked to a shorter length of stay.

Subclinical leaflet thrombosis after TAVR CT JAMA Cardiology OAC

Subclinical leaflet thrombosis after TAVR: What we know, and still need to learn, about a challenging complication

Treating subclinical leaflet thrombosis after TAVR has been an ongoing challenge for structural heart clinicians, but recent research has gone a long way toward improving our understanding of this important topic. 

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

TAVR outcomes take a hit when patients present with heart failure or hypertrophic cardiomyopathy

In-hospital mortality was especially high among TAVR patients presenting with hypertrophic cardiomyopathy, according to a new analysis.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.